• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC IRELAND RESOLUTE INTEGRITY RX; STENT, CORONARY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC IRELAND RESOLUTE INTEGRITY RX; STENT, CORONARY, DRUG-ELUTING Back to Search Results
Lot Number UNKNOWN
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Myocardial Infarction (1969); Thrombus (2101)
Event Date 09/09/2019
Event Type  Injury  
Manufacturer Narrative
Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents https://doi.Org/10.1016/j.Jcin.2019.04.054.Patient death(s) were also included in the results of the journal article, however no causal link suggesting that the medtronic device(s) caused or contributed to the death(s) was provided.Information is provided in the future, a supplemental report will be issued.
 
Event Description
This 3-arm clinical trial enrolled 3,514 all-comer patients who required percutaneous coronary intervention with drug eluting stents (des) implantation between (b)(6) 2012 and (b)(6) 2015.Of the 3,514 patients enrolled in this study, 1,173 patients were implanted with resolute integrity stents.938 patients had at least one complex lesion, 409 patients with at least one bifurcation lesion, 48 patients with at least one chronic total occlusion, 30 with at least one bypass graft, 81 with at least one ostial lesion and 265 with at least one severely calcified lesion.1,131 patients completed 3 year follow-up.The use of dual antiplatelet therapy (dapt) at 3 years was low (6.9%), as was the use of oral anti coagulation therapy plus antiplatelet agents (0.9%), without any between-des difference clinical outcomes included death, myocardial infarction, target vessel revascularization, target lesion revascularization, non¿target vessel revascularization and stent thrombosis.Despite substantial differences in stent backbone and polymer coating, all 3 des showed favorable 3-year safety and efficacy in all comers, without significant between-stent differences.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
RESOLUTE INTEGRITY RX
Type of Device
STENT, CORONARY, DRUG-ELUTING
Manufacturer (Section D)
MEDTRONIC IRELAND
parkmore business park west
galway
Manufacturer (Section G)
MEDTRONIC IRELAND
parkmore business park west
galway
Manufacturer Contact
toni o'doherty
parkmore business park west
galway 
091708734
MDR Report Key9184906
MDR Text Key162353584
Report Number9612164-2019-04327
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeNL
PMA/PMN Number
P110013
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Type of Report Initial
Report Date 10/14/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 09/18/2019
Initial Date FDA Received10/14/2019
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age64 YR
-
-